Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.48 |
| ▸ | NQO2 | P16083 | 4/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.36 |
| ▸ | KDM6B | O15054 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076764 | 0.92 | MTNR1A (0.55) | MTNR1AMTNR1BNQO2KDM4C | |
| SCHEMBL6076702 | 0.79 | MTNR1A (0.56) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5223865 | 0.76 | MTNR1A (0.63) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5231694 | 0.75 | MTNR1A (0.58) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL6076698 | 0.72 | MTNR1A (0.64) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL6075869 | 0.72 | KDM4C (0.46) | KDM4CKDM6B | |
| SCHEMBL6077449 | 0.71 | SMN1; SMN2 (0.43) | MTNR1AMTNR1BKDM4CKDM6B | |
| SCHEMBL5223857 | 0.70 | MTNR1A (0.72) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL7021471 | 0.68 | MTNR1A (0.86) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL6077048 | 0.67 | MTNR1A (0.44) | MTNR1AMTNR1BKDM4CKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| EP-1077927-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058495-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885MTNR1B 414/4885NQO2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.